team@relentlesshealthvalue.com
For verified host and producer emails, sign up to view.
Episodes: 400
Frequency: Weekly
Rating: 4.9/5.0
Estimated listeners: 1k-10k
Gender skew: Neutral
Location: USA
YouTube: 319 subscribers
team@relentlesshealthvalue.com
For verified host and producer emails, sign up to view.
Stacey Richter - Healthcare industry commentator focused on exposing administrative waste, hidden fees, and misaligned incentives in the U.S. healthcare system, while translating complex healthcare issues into prac...
Andrew Tsang - Revenue Cycle Management, Administrative Waste, Payment Disputes, Prior Authorization, Stop-loss Coverage, And Direct Contracting.
Lisa Rosenbaum, MD - Primary Care, Physician Incentives, Cognitive Atrophy, Referral Patterns, Relational Expertise, And Fragmented Care.
How GoodRx Actually Makes Money: PBMs, Cash Prices, and Pharmacy Contracts, With Ge Bai, PhD, CPA (EP522)
July 29, 2026
Ask Me Anything: How Does GoodRx Actually Make Money, and Who Really Pays for the Discount? Episode 522. A listener asked Stacey Richter a deceptively simple question: how exactly does GoodRx make money? To answer it, this AMA episode revisits a 2021 conversation with Ge Bai, PhD, CPA, professor of accounting at the Johns Hopkins Carey Business School and of health policy and management at the Johns Hopkins Bloomberg School of Public Health, recently nominated to serve as Assistant Secretary ...
How Revenue Cycle Management (RCM) Became an Over $200 Billion Healthcare Hot Potato, With Andrew Tsang. EP521
July 22, 2026
RCM: Why Revenue Cycle Management Is Healthcare's $200B Hot Potato, With Andrew Tsang (EP521) Revenue cycle management (RCM) sounds like the least sexy phrase in healthcare — a back-office spreadsheet problem. It isn't. Andrew Tsang, an independent healthcare analyst and writer of the Substack Health Is Other People, with 15+ years across providers, payers, consulting, and policy, joins Stacey Richter to unpack how RCM has grown into a $200-plus-billion industry that eats roughly a third of e...
Cash-Pay Generic Drugs Are a Functioning Market in Healthcare—Policymakers Beware and Be Careful. EP520
July 15, 2026
Cash-Pay Generic Drugs and the PBM Spread Pricing Problem (EP520) Cash-pay generic drugs are one of the few corners of US healthcare where a real, functioning market already exists — which is why Stacey Richter argues policymakers need to tread carefully when trying to "fix" drug affordability. In this solo episode, Stacey explains why cash generic prices can run as low as $1 a prescription, then plays clips from four past guests — Ge Bai, PhD, CPA; Bryce Platt, PharmD; Benjamin Jolley, Pharm...
Try us risk free with a FREE 3 days trial.
Join hundreds of PR teams using Podseeker to pitch and land bookings